Lurtotecan Liposome

A liposome-encapsulated formulation of lurtotecan with antineoplastic activity. Lurtotecan, a semisynthetic analogue of camptothecin, selectively stabilizes the topoisomerase I-DNA covalent complex and forms an enzyme-drug-DNA ternary complex during S phase of the cell cycle, thereby inhibiting religation of topoisomerase I-mediated single-stranded DNA breaks. This ultimately results in an inhibition of DNA replication, inducing double-stranded DNA breakages, obstruction of RNA and protein synthesis and triggering apoptosis. Furthermore, this agent also stimulates degradation of topoisomerase I, likely mediated through ubiquitin-proteasomal pathway. Liposomal delivery of lurtotecan improves its penetration and delivery into tumors while lowering systemic side effects. (NCI Thesaurus)

YOU MAY ALSO LIKE

Lurtotecan

An anticancer drug that belongs to the family of drugs called topoisomerase inhibitors.

Lupus Panniculitis

Lupus erythematosus primarily affecting the subcutaneous adipose tissues.

Lupus Glomerulonephritis

Glomerulonephritis associated with systemic lupus erythematosus. It is classified into four histologic types: mesangial, focal, diffuse, and membranous.

Lupus Erythematosus

An autoimmune, connective tissue chronic inflammatory disorder affecting the skin, joints, kidneys, lungs, heart, and the peripheral blood cells. It is more…

Lupus Anticoagulant Sensitive APTT Measurement

The determination of the amount of time that it takes for clotting to occur when a lupus sensitive reagent is added to…

Lupus Anticoagulant Antibody

Antibodies directed against plasma proteins (such as beta-2-glycoprotein I, prothrombin, or annexin V) bound to anionic phospholipids. The anticoagulant blocks in vitro…